PortfoliosLab logoPortfoliosLab logo
GILT vs. AQST
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

GILT vs. AQST - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Gilat Satellite Networks Ltd (GILT) and Aquestive Therapeutics, Inc. (AQST). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, GILT achieves a 15.92% return, which is significantly higher than AQST's -35.45% return.


GILT

1D
-2.41%
1M
-4.15%
YTD
15.92%
6M
18.30%
1Y
138.10%
3Y*
37.66%
5Y*
6.65%
10Y*
14.56%

AQST

1D
-0.95%
1M
0.97%
YTD
-35.45%
6M
-32.85%
1Y
25.98%
3Y*
22.65%
5Y*
-0.29%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

GILT vs. AQST - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
GILT
Gilat Satellite Networks Ltd
15.92%110.41%0.65%5.34%-17.96%18.14%-12.01%-9.43%7.64%
AQST
Aquestive Therapeutics, Inc.
-35.45%81.46%76.24%123.92%-76.81%-27.29%-8.08%-7.62%-58.14%

Correlation

The correlation between GILT and AQST is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.22

Correlation (3Y)
Calculated over the trailing 3-year period

0.19

Correlation (5Y)
Calculated over the trailing 5-year period

0.21

Correlation (All Time)
Calculated using the full available price history since Jul 25, 2018

0.21

Fundamentals

Market Cap

GILT:

$1.16B

AQST:

$511.28M

EPS

GILT:

$0.49

AQST:

-$0.61

PS Ratio

GILT:

2.09

AQST:

9.42

Total Revenue (TTM)

GILT:

$470.09M

AQST:

$50.27M

Gross Profit (TTM)

GILT:

$142.60M

AQST:

$20.92M

EBITDA (TTM)

GILT:

$56.44M

AQST:

-$53.08M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GILT vs. AQST — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GILT
GILT Risk / Return Rank: 8787
Overall Rank
GILT Sharpe Ratio Rank: 8989
Sharpe Ratio Rank
GILT Sortino Ratio Rank: 8383
Sortino Ratio Rank
GILT Omega Ratio Rank: 8484
Omega Ratio Rank
GILT Calmar Ratio Rank: 8989
Calmar Ratio Rank
GILT Martin Ratio Rank: 8888
Martin Ratio Rank

AQST
AQST Risk / Return Rank: 5656
Overall Rank
AQST Sharpe Ratio Rank: 5454
Sharpe Ratio Rank
AQST Sortino Ratio Rank: 5959
Sortino Ratio Rank
AQST Omega Ratio Rank: 6262
Omega Ratio Rank
AQST Calmar Ratio Rank: 5353
Calmar Ratio Rank
AQST Martin Ratio Rank: 5252
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GILT vs. AQST - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Gilat Satellite Networks Ltd (GILT) and Aquestive Therapeutics, Inc. (AQST). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


GILTAQSTDifference
Sharpe ratioReturn per unit of total volatility

+1.63

Sortino ratioReturn per unit of downside risk

+1.32

Omega ratioGain probability vs. loss probability

1.33

1.16

+0.17

Calmar ratioReturn relative to maximum drawdown

3.97

0.43

+3.54

Martin ratioReturn relative to average drawdown

9.96

0.81

+9.14

GILT vs. AQST - Sharpe Ratio Comparison

The current GILT Sharpe Ratio is 1.94, which is higher than the AQST Sharpe Ratio of 0.31. The chart below compares the historical Sharpe Ratios of GILT and AQST, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

GILT vs. AQST - Drawdown Comparison

The maximum GILT drawdown since its inception was -99.94%, roughly equal to the maximum AQST drawdown of -96.68%. Use the drawdown chart below to compare losses from any high point for GILT and AQST.


Loading charts...

Drawdown Indicators


GILTAQSTDifference

Max Drawdown

Largest peak-to-trough decline

-99.94%

-96.68%

-3.26%

Max Drawdown (1Y)

Largest decline over 1 year

-34.96%

-60.61%

+25.65%

Max Drawdown (3Y)

Largest decline over 3 years

-41.94%

-63.55%

+21.61%

Max Drawdown (5Y)

Largest decline over 5 years

-63.20%

-90.11%

+26.91%

Max Drawdown (10Y)

Largest decline over 10 years

-80.89%

Current Drawdown

Current decline from peak

-99.47%

-78.01%

-21.46%

Average Drawdown

Average peak-to-trough decline

-80.78%

-76.92%

-3.86%

Ulcer Index

Depth and duration of drawdowns from previous peaks

13.93%

32.01%

-18.08%

Volatility

GILT vs. AQST - Volatility Comparison

Gilat Satellite Networks Ltd (GILT) has a higher volatility of 25.22% compared to Aquestive Therapeutics, Inc. (AQST) at 21.51%. This indicates that GILT's price experiences larger fluctuations and is considered to be riskier than AQST based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GILTAQSTDifference

Volatility (1M)

Calculated over the trailing 1-month period

25.22%

21.51%

+3.71%

Volatility (6M)

Calculated over the trailing 6-month period

60.23%

68.41%

-8.18%

Volatility (1Y)

Calculated over the trailing 1-year period

71.60%

85.07%

-13.47%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

48.93%

82.62%

-33.69%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

47.79%

87.69%

-39.90%

Dividends

GILT vs. AQST - Dividend Comparison

Neither GILT nor AQST has paid dividends to shareholders.


PositionTTM2025202420232022202120202019
AQST
Aquestive Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
GILT
Gilat Satellite Networks Ltd
0.00%0.00%0.00%0.00%0.00%8.91%5.52%5.71%

Financials

GILT vs. AQST - Financials Comparison

This section allows you to compare key financial metrics between Gilat Satellite Networks Ltd and Aquestive Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M100.00M120.00M140.00M20222023202420252026
110.47M
14.45M
(GILT) Total Revenue
(AQST) Total Revenue
Values in USD except per share items

GILT vs. AQST - Profitability Comparison

The chart below illustrates the profitability comparison between Gilat Satellite Networks Ltd and Aquestive Therapeutics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%20222023202420252026
34.1%
0
Portfolio components
GILT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Gilat Satellite Networks Ltd reported a gross profit of 37.65M and revenue of 110.47M. Therefore, the gross margin over that period was 34.1%.

AQST - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Aquestive Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 14.45M. Therefore, the gross margin over that period was 0.0%.

GILT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Gilat Satellite Networks Ltd reported an operating income of 5.43M and revenue of 110.47M, resulting in an operating margin of 4.9%.

AQST - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Aquestive Therapeutics, Inc. reported an operating income of -4.20M and revenue of 14.45M, resulting in an operating margin of -29.1%.

GILT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Gilat Satellite Networks Ltd reported a net income of 5.23M and revenue of 110.47M, resulting in a net margin of 4.7%.

AQST - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Aquestive Therapeutics, Inc. reported a net income of -8.06M and revenue of 14.45M, resulting in a net margin of -55.8%.


Frequently Asked Questions


GILT and AQST have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

GILT has higher volatility (25.22%) compared to AQST (21.51%). In terms of maximum drawdown, GILT dropped -99.94% vs AQST's -96.68%.

GILT currently has the higher Sharpe Ratio (1.94 vs 0.31), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for GILT and AQST

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer